MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer - Wikidata - awgldk - TriplyDB

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

http://www.wikidata.org/entity/Q33443571

about

Oncoproteomic profiling with antibody microarrays MET inhibitors in combination with other therapies in non-small cell lung cancer Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.Targeting the HGF/Met signalling pathway in cancer.TAM receptors in leukemia: expression, signaling, and therapeutic implications.Targeting the HGF/Met signaling pathway in cancer therapy AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Targeting homologous recombination-mediated DNA repair in cancer.A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates.Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation.Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.[Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].

P2860

Q21183955-D2E281EB-D993-4215-A56E-58909BE61CAF Q26823203-A7ACD4D5-C7A9-4428-A6C2-EDE029458274 Q33415437-10C20D50-C8E9-4274-A49D-E9992B642506 Q34121332-08B1B2C3-5A82-49DA-858C-3B8ADEF61F5E Q34141913-8722E19F-5CDA-410F-96D4-7AB077191B85 Q34253654-C4DEDEFB-F514-49DC-AEE5-D6D75BDD7FA8 Q34985562-BD1014AA-C9CE-4FBF-A07E-EAE375CC99EF Q35262625-F2B9AD7D-4948-48C0-B5AA-8222EE396289 Q35677075-2123BA83-9C7E-40C4-A3B8-D1E94FE0B23E Q35927501-1F5485A0-9D0A-4A72-8A5A-089B82DD4BC0 Q36142604-A848F7EE-11C0-4DB9-A801-B3F3F228B01B Q36865209-325EB770-4E36-4F00-8284-5EC27E99A61E Q37013777-CD3302C6-044F-4135-B2D7-6D3D0F5E3FE3 Q37715171-6C7A20E3-AB55-4288-97EE-81EF13263F99 Q37968256-D63B37B8-C47E-4714-B4D6-9A30BE50078E Q38184667-261C15BF-7DA7-450E-8938-90373C6519C9 Q38460859-D6C5106F-D332-4F3C-A316-6EDFCE48E073 Q44516282-916B3D56-B846-4684-82AE-3B05BD6ADB97 Q50455684-1705D7CF-5257-4378-8770-11C86D812CDD Q51152435-007896B2-DE06-4AEA-BCBB-F104D613C488 Q53134314-C3C6F360-3C1F-4021-9491-6DEFE47C34EE Q53232399-656E4669-FDA5-4C29-8A1F-ABA5B5DF7278

P2860

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

http://www.wikidata.org/entity/Q33443571

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@ast

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@en

type

label

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@ast

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@en

prefLabel

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@ast

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@en

P1433

Q33443571-0A6A44BB-A65D-4EAF-9EE1-E0DF49A92899

P1476

Q33443571-0C969B5E-C6E7-4B9D-9978-945C1459FA9C

P2093

Q33443571-17DCB184-BBBA-4DFB-83F5-4E6DE174541F

Q33443571-2C2153A6-EF9D-46F2-B5DE-49E7749FEEB0

Q33443571-48B7C3F4-A36B-4C79-B7AD-7240B328CA41

Q33443571-A13422FF-9745-4A06-AF17-74DAE867E307

Q33443571-B312E719-3706-40AF-A867-A0CBEB7A0452

Q33443571-C689890F-041F-48E5-951F-D0A929BFBD00

P2860

Q33443571-018853FA-7308-4E14-BDDA-BE45952DC4B0

Q33443571-047D5203-B1B7-4D8D-AC20-374231F28FDE

Q33443571-04B834EC-0922-424A-B83F-1600B187685B

Q33443571-0BED64F5-4305-4112-B0A8-5B03A2E064F8

Q33443571-12631561-46C9-4975-9683-DDDF21FA0118

Q33443571-1B930381-EE1B-4C76-A7E0-79369BA9F314

Q33443571-1BF9CF42-25F9-4A84-B168-416B1DB4B5CA

Q33443571-231DAEF3-3313-42AA-AADA-230D17B71C61

Q33443571-27DA2395-7BFB-4ABC-A240-791A011E7BA0

Q33443571-2A6DF648-9BB4-4C5B-8879-011F0628D556

P2888

Q33443571-175EFB41-C346-4CFA-AFAF-A6C876D8C9B9

P304

Q33443571-76E871F8-598C-4606-A42B-5666967F78D9

P31

Q33443571-94FEDF85-5920-46CB-8521-F736EFDF7613

P356

Q33443571-1482E642-3A2D-46FC-A3F5-07AF284DF7AD

P407

Q33443571-21CBFD64-D419-4430-B1CC-A0D4005D13BE

P478

Q33443571-68DE0BC8-7DF6-4E4F-9A27-A43D701F1179

P50

Q33443571-06B27A9B-6BE2-49EC-9E4D-401A2FE4A1B8

Q33443571-29BF92E7-B7B3-482F-A562-6DE05509B781

P577

Q33443571-6D1050E4-8906-414F-B5D9-96D8181105B4

P5875

Q33443571-4F3BD62A-C9BE-4ACC-8CF3-D80F977F0DAF

P6179

Q33443571-3A2E51BD-9B4A-4A49-B4FB-4C12FD9D18BC

P698

Q33443571-70B98A00-9072-47E0-89BB-570FC6532ADC

P932

Q33443571-EC1219D5-DBF1-4B18-A785-DC5A2DCAE2DD

P356

1471-2407-9-142

P1433

P1476

MP470, a novel receptor tyrosi ...... umor growth in prostate cancer

@en

P2093

Amy Stejskal

http://www.w3.org/2001/XMLSchema#string

Daruka Mahadevan

http://www.w3.org/2001/XMLSchema#string

Jose W Saldanha

http://www.w3.org/2001/XMLSchema#string

Kimiko Della Croce

http://www.w3.org/2001/XMLSchema#string

Larry S Cooke

http://www.w3.org/2001/XMLSchema#string

Wenqing Qi

http://www.w3.org/2001/XMLSchema#string

P2860

A tyrosine kinase profile of prostate carcinoma

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Cell signaling by receptor tyrosine kinases

The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells

Cancer statistics, 2007

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Signal transduction in prostate cancer progression.

LNCaP model of human prostatic carcinoma.

Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems.

Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins.

P2888

1471-2407-9-142

P304

142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-9-142

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

David J. Bearss

Christopher Riley

P577

2009-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24418523

http://www.w3.org/2001/XMLSchema#string

P6179

1034349763

http://www.w3.org/2001/XMLSchema#string

P698

19432987

http://www.w3.org/2001/XMLSchema#string

P932

2685437

http://www.w3.org/2001/XMLSchema#string